Skip to content
Biotechnology, Finance Investment

Phantm raises $2M to spearhead plastic reduction for Australian businesses

Phantm 2 mins read

Phantm, a new plastic reduction platform committed to addressing one of the world’s largest waste issues and accelerating the adoption of natural materials, has successfully secured $2 million in an oversubscribed seed round, led by Blacknova VC, Salus Ventures and CoVentures VC. With Elliot Costello at the helm, Phantm is already working with a range of leading international and Australian businesses, including MECCA, Starbucks Australia and Norwood Industries.

 

Phantm’s primary objective is to provide an independent pathway for businesses seeking to reduce their plastic footprint through making informed packaging and product decisions.

By providing access to industry-leading plastic and natural materials experts, Phantm helps businesses meet their ESG goals, and move towards a positive impact on people and planet. Its robust methodology, known as A-R-T (Assess, Reduce, Transition), assists firms in reducing costs and tracking their progress towards becoming plastic-free.

 

Elliot Costello, Cofounder and CEO of Phantm commented, "We're in the midst of a plastic crisis, and recycling alone cannot solve it. The market has been demanding alternatives, and it's time to embrace the range of different materials that can replace petrochemical plastics so that we can finally turn virgin plastic off at the tap. The enthusiasm from investors across the country is really exciting and shows the dedication to deplastifying Australian businesses." 

 

The plastic industry's value exceeds $600 billion USD, and consumption could nearly double by 2050 unless urgent action is taken. Globally, only 9% of plastics are recycled, with contamination and mixed plastics often hampering any recycling potential. This is in addition to the reduced quality when recycling plastics, which not only restricts reusability but also incurs higher costs compared to producing new virgin plastic.

 

These economic factors, infrastructure limitations, and diverse regulations make recycling challenging, which makes the increasing emergence of natural materials (such as seaweed, fungi, cellulose, pulp, and PHA based materials) a compelling alternative to tap into.

 

Edward Whitehead, Phantm’s Head of Strategy and global plastics expert, says Phantm utilises its verified understanding to assist brands who are otherwise fearful or hesitant to navigate the complex layers involved in plastic reduction.

 

“We bring the expertise that helps firms pull back the layers, ensuring they're taking the right steps towards positive change. Businesses can’t just leapfrog into perfection, and it's important they work transparently to improve, be better and do better”.

 

Though currently operating within Australia, the platform is dedicated to the global plastic crisis, with plans to expand across Asia, North America, and European markets. Doing so will support regions with significant plastic consumption and limited recycling infrastructure.

 

To learn more information about the platform or to get started in reducing your business’s plastic footprint visit phantm.com 

 


About us:

Media Interviews:

  • Elliot Costello, CoFounder and CEO

  • Edward Whitehead, Head of Strategy - global plastics expert

  • Kaitlin Harasym, Head of Growth & Engagement

  • Matt Kendall, Head of Brand

 

About Phantm:

Phantm is on a mission to eliminate plastic from the world's supply chains. Led by Elliot Costello, Phantm provides trusted guidance to businesses and brands looking to assess their plastics usage and transition from plastic to natural materials. By offering a comprehensive approach to reducing plastic usage and meeting ESG goals, Phantm is a pioneering force in the global effort to deplastify industries and create a regenerative future.


Contact details:

Prue Bowtell | 0431 081 200 | prue@thebraveryishere.com

Megan Bentley | 0452 214 611 | megan@thebraveryishere.com

More from this category

  • Finance Investment
  • 06/09/2024
  • 20:40
Hut 8 Corp.

Hut 8 Operations Update for August 2024

18.5 EH/s and 762 MW under management in miningEnergized Building 1 at CedarvaleMIAMI, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Hut 8 Corp. (Nasdaq | TSX: HUT) (“Hut 8” or the “Company”), a leading, vertically integrated operator of large-scale energy infrastructure and one of North America’s largest Bitcoin miners, today released its operations update for August 2024.“During August, we maintained our focus on low-cost operations and unit economics,” said Asher Genoot, CEO of Hut 8. “Maximizing returns from our current fleet remains a priority while we continue to plan a thoughtfully structured fleet upgrade to next-generation ASICs. Reactor, our curtailment software, enabled…

  • Finance Investment, Government Federal
  • 06/09/2024
  • 18:34
The professional bodies representing Australia's tax and BAS agents

JOINT BODIES REMAIN CONCERNED ABOUT NEW TAX AGENT OBLIGATIONS AFTER ROUNDTABLE

6 September 2024 The professional bodies representing Australia’s tax and BAS agents met with the Assistant Treasurer’s office and Treasury today to discuss our ongoing concerns regarding the Tax Agent Services (Code of Professional Conduct) Determination 2024. The Assistant Treasurer’s office and Treasury acknowledged our concerns with sections 15 and 45 of the Determination and we are pleased they are open to making the necessary changes to address them. However, there is still considerable work to be done and further consultation required. The joint bodies* made it clear today that the proposed amendments will still make our members’ work challenging,…

  • Contains:
  • Biotechnology
  • 06/09/2024
  • 12:00
Cleo Diagnostics Limited. ASX.COV

Cleo Commences U.S. Clinical Trials for its Ovarian Cancer Diagnostic Blood Test

Highlights U.S. clinical trials commenced with first patients enrolled over 8 recruitment centres Trial will validate the use ofCLEO’s ovarian cancer blood test for the U.S. market Pathway set toward FDA submission in CY2025. ___________ MELBOURNE, AUSTRALIA, 6 September 2024: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to confirm the commencement of U.S. clinical trials for its ovarian cancer diagnostic blood test. Commencement of U.S. Clinical Trials CLEO’s pivotal FDA-enabling clinical trial has commenced in the United States, with first patients recruited into the study. The trial is designed to benchmarkCLEO’s technology, with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.